(Total Views: 426)
Posted On: 03/19/2021 12:02:24 PM
Post# of 145902
“As of November 2020, late-stage clinical studies for numerous repurposed antibody therapeutics (Table 1) were recruiting patients, and emergency use authorizations (EUAs) had been requested or granted for 3, anti-IL-6 receptor levilimab, anti-CD6 itolizumab, and anti-C-C chemokine receptor type 5 (CCR5) leronlimab.“
Looks like they did request EUA for CD10 ? Although they said they didn’t? Maybe this is accurate but I found it interesting.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833761/
I find it comical and also disgusting at the same time how BP get EUA for all their drugs while Leronlimab sits on the shelves. What a joke.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)